Table 2.
Resistance rates for clinical P. aeruginosa isolates.
| Antibiotic | Number (%) of resistant isolates | |||
|---|---|---|---|---|
| Total isolates (n = 122) |
Imipenem susceptible (n = 66) |
Imipenem intermediate (n = 8) |
Imipenem resistant (n = 48) |
|
| β-lactams | ||||
| Cefuroxime | 107 (87.7%) | 51 (77.2%) | 8 (100%) | 48 (100%) |
| Cefoperazone | 98 (80.3%) | 43 (65.2%) | 8 (100%) | 47 (97.9%) |
| Ceftazidime | 74 (60.6%) | 23 (34.8%) | 8 (100%) | 43 (89.5%) |
| Meropenem | 56 (45.9%) | 3 (4.5%) | 7 (87.5%) | 46 (95.8%) |
| Aztreonam | 55 (45.1%) | 28 (42.4%) | 3 (37.5%) | 24 (50%) |
| Imipenem | 48 (39.3%) | 66 (100%) | 8 (100%) | 48 (100%) |
| Piperacillin/tazobactam | 31 (25.4%) | 4 (6.1%) | 7 (87.5%) | 20 (41.6%) |
| Non β-lactams | ||||
| Gentamicin | 61 (50%) | 13 (19.7%) | 5 (62.5%) | 43 (89.5%) |
| Ciprofloxacin | 53 (43.4%) | 17 (25.8%) | 5 (62.5%) | 31 (64.5%) |
| Amikacin | 40 (32.8%) | 9 (13.6%) | 7 (87.5%) | 24 (50%) |
| Polymyxin B | 3 (2.4%) | 0 (0.0%) | 1 (12.5%) | 2 (4.2%) |